Genmab maintained by Merrill Lynch at buy

Genmab was maintained by Merrill Lynch analyst Peter Welford at a buy rating with a price target on the stock of DKK 150 following second-quarter results. ON the Copenhagen exchange, Genmab shares Wednesday were down DKK 0.50, or 0.49%, at DKK 101.00 on volume of 177,761 shares versus the three-month running average of 78,582.3 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.